

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

Examiner:

To Be Assigned

BACQUÉ, et al

Art Unit:

To Be Assigned

Application No.:

10/622,655

Filed:

July 18, 2003

Title:

Quinolypropylpiperidine Derivatives, **Preparation Process and Intermediates,**

and Compositions Including Them

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to Commissioner of Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on

September 11, 2003

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. 1.56, 1.97 AND 1.98

Mail Stop Commissioner of Patents P. O. Box 1450 Alexandria, VA 22313-1450

Sir:

Applicants submit herewith patents, publications, and other information of which they are aware, which they believe may be material, as defined in 37 C.F.R. 1.56(b), to the examination of this application and in respect of which there may be a duty to disclose in accordance with 37 C.F.R. 1.56(a). While the information referred to in this Information Disclosure Statement may be material pursuant to 37 C.F.R. 1.56(b), the filing of this Information Disclosure Statement is not intended to, pursuant to 37 C.F.R. 1.97(h), constitute an admission that any patent, publication or other information referred to is, or is considered to be, material to the patentability of this invention. Pursuant to 37 C.F.R. 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information exists.

 \boxtimes This Information Disclosure Statement is filed within the period set forth in §1.97(b) (a) because it accompanies the new patent application submitted herewith, is filed within three months of the filing date of a national application or within three months of the date of entry of the national stage as set forth in §1.491 in an international application, or is believed to be filed before the mailing date of a first Office Action on the merits, whichever event occurs last. However, in the event that the first office action has been mailed, the Commissioner is authorized to charge any fees under 37 C.F.R. 1.17(p) or credit any overpayment to Account No. 18-1982.

This Information Disclosure Statement is filed after the period set forth in 37 C.F.R. П (b) 1.97(b), but is believed to be filed before the mailing date of a final action under §1.113 or a notice of allowance under §1.311, whichever occurs first. The undersigned attorney certifies that each item of information contained in this (1) Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement; (2) The undersigned attorney certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned attorney after making reasonable inquiry, was known to any individual designated in §1.56(c) more than three months prior to the filing of this statement; or **(3)** This Information Disclosure Statement is accompanied by a transmittal letter in which payment of the fee set forth in §1.17(p) and required by 37 C.F.R. 1.97(c) is authorized.

Please note that:

- (1) No English language equivalent of FR 2,354,771 was found, but an English abstract is enclosed with the French patent.
- (2) U.S. Patents Publication No. 2002/0111492 A1 and U.S. Patent No. 6,403,610 B1 are enclosed as English language equivalents of commonly owned WO 02/40474 and WO 01/25227, respectively. In each case, they are accompanied by only the cover sheet of the corresponding, non-English, WO publication.
- (3) For completeness, a copy of the French search report is also enclosed.

Respectfully submitted,

Itving Newman, Reg. No. 22,638 Attorney/Agent for Applicant

Aventis Pharmaceuticals Inc.

Patent Department

Route #202-206 / P.O. Box 6800

Bridgewater, NJ 08807-0800

Telephone (908) 231-2785

Telefax (908) 231-2626

Aventis Docket No. FRAV2002/0019US NP

Please t	ype a	plus sign	(+) inside	this box	-
----------	-------	-----------	----	----------	----------	---

PTO/SB/08A (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

rade Under the Paperwork Reduction Act of 1995, no persons to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet	1	of	2	
Oncot	ļ •	01	_	

Complete if Known					
Application Number	10/622,655				
Filing Date	07-18-2003				
First Named Inventor	BACQUE				
Group Art Unit					
Examiner Name					
Attomey Docket Number	FRAV2002/0019 - US - NP				

				U.S. PATENT DOCUM	MENTS	
Examiner Initials*	Cite No. ¹	U.S. Patent Document Kind Code ² Number (if known)		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		2002/0111492	A1	English equivalent of WO 02/40474		
	•	6,403,610 B1		English equivalent of WO 01/25227		
					7.0%	
						· · · · · · · · · · · · · · · · · · ·
				****		WHE

				FOR	EIGN PATENT DOCUMEN	TS		
Examiner Initials	Cite No.1	Office	Foreign Patent Do Number4	cument Kind Code⁵ (if known)	Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ₆
		EP	0 030 044		TRIJZELAAR et al	06-10-1981		
		FR	2 354 771		CHAMPSEIX	01-13-1978		
		wo	00/43383		DAVIES et al	07-27-2000		
		wo	99/37635		COATES et al	07-29-1999		
		wo	02/40474		BACQUE	05-23-2002		1
		wo	01/25227		MALLERON	04-12-2001		\Box
								╁
			· · · · · · · · · · · · · · · · · · ·					_

Examiner	Date	
Signature	Considered	

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. 2 See attached Kinds of U.S. Patent Documents. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

		3176	
Please type a plus sign (+) inside this box →	SEP	1 5 2003	C26
Under the Paperwork Reduction Act of 1995, no person	13	ired to resp	

PTO/SB/08B (10-96)
Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute	e for form 1449B/I	то	MORMAN	Complete if Known			
				Application Number	10/622,655		
INFC	PRMATIC)N DI	SCLOSURE	Filing Date	07-18-2003		
STA	TEMENT	BY A	APPLICANT	First Named Inventor	BACQUE		
0.7.		,		Group Art Unit			
(use as many sheets as necessary)				Examiner Name			
Sheet	2	of	2	Attorney Docket Number	FRAV2002/0019 - US - NP		

	OTHER PRIOR ART NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T²			
	-					
Examine Signature		Date Considered				

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.